The present invention relates to compounds and pharmaceutical preparations and their use in therapy for preventing or treating trauma, ischemia, stroke and degenerative diseases associated with cell death. Methods and compositions of the invention are particularly useful for treating neurological disorders associated with cellular necrosis.
QUINAZOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS
申请人:Amgen Inc.
公开号:EP1994021A2
公开(公告)日:2008-11-26
[EN] QUINAZOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS<br/>[FR] DERIVES DE QUINAZOLINE EN TANT QU'INHIBITEURS DE LA PHOSPHODIESTERASE 10
申请人:AMGEN INC
公开号:WO2007103370A2
公开(公告)日:2007-09-13
[EN] The present invention if directed to certain quinazoline compounds that are PDE10 inhibitors, pharmaceutical compounds containing the same and processes for preparing the same. The invention is also directed to methods of treating diseases treatable by PDE10 enzyme such as obesity, non-insulin dependent diabetes, schizophrenia or bipolar disorder, obsessive-compulsive disorder, and the like. [FR] La présente invention concerne certains composés de quinazoline qui sont des inhibiteurs de PDE10, des composés pharmaceutiques les contenant et des procédés de préparation de ceux-ci. La présente invention concerne également des procédés de traitement des maladies traitables par l'enzyme PDE10 telles que l'obésité, le diabète non insulinodépendant, la schizophrénie ou un trouble bipolaire, le trouble obsessionnel compulsif et analogue.
Quinazoline derivatives as phosphodiesterase 10 inhibitors
申请人:Liu Ruiping
公开号:US20070265258A1
公开(公告)日:2007-11-15
The present invention if directed to certain quinazoline compounds that are PDE10 inhibitors, pharmaceutical compounds containing the same and processes for preparing the same. The invention is also directed to methods of treating diseases treatable by PDE10 enzyme such as obesity, non-insulin dependent diabetes, schizophrenia or bipolar disorder, obsessive-compulsive disorder, and the like.